Found: 7
Select item for more details and to access through your institution.
BAY 58-2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers.
- Published in:
- 2007
- By:
- Publication type:
- Abstract
BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers.
- Published in:
- 2007
- By:
- Publication type:
- Abstract
Effects of omeprazole and AlOH/MgOH on riociguat absorption.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Migration eines Plexus-axillaris-Katheter-Fragments : Eine bei der Entfernung unbemerkt abgetrennte Katheterspitze wandert ins Zentralnervensystem.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Activator Cinaciguat (BAY 58-2667) in Healthy Male Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2008, v. 48, n. 12, p. 1400, doi. 10.1177/0091270008322906
- By:
- Publication type:
- Article
Single-Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63-2521: An Ascending-Dose Study in Healthy Male Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2008, v. 48, n. 8, p. 926, doi. 10.1177/0091270008319793
- By:
- Publication type:
- Article
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.
- Published in:
- Pulmonary Circulation, 2016, v. 6, p. S43, doi. 10.1086/682228
- By:
- Publication type:
- Article